REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Triple-Drug cocktail shows promise against CLL
Disease control OngoingThis study is testing a combination of three drugs—obinutuzumab, ibrutinib, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the best dose and see how well the combination …
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Kerry Rogers • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis early-phase trial is testing a combination of three drugs—lenalidomide, ibrutinib, and rituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. The main goal is to find the safest …
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo targets Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests a new two-drug combination (pevonedistat and ibrutinib) in adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effec…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for tough blood cancers: experimental drug enters human testing
Disease control OngoingThis early-stage study is testing an experimental drug called BGB-21447 in about 112 people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after prior treatments. The main goal is to find a safe dose and check for side effects, while als…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Triple-Drug cocktail aims to boost remission in CLL
Disease control OngoingThis phase 2 study is testing a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if this triple therapy can improve complete remission rates. The study enrolle…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug combo shows promise for Tough-to-Treat leukemia
Disease control OngoingThis phase II trial tests a combination of two targeted drugs, venetoclax and ibrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The study includes patients whose cancer has come back or is hard to treat, as well as some untreated patients…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could taking drug breaks tame leukemia side effects?
Disease control OngoingThis study tests whether taking duvelisib on an irregular schedule can control chronic lymphocytic leukemia or small lymphocytic lymphoma as well as the standard daily dosing, but with fewer severe side effects. Fifteen adults with cancer that returned or didn't respond to prior …
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Engineered immune cells take aim at Tough-to-Treat blood cancers
Disease control OngoingThis early-phase trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell lymphomas or chronic lymphocytic leukemia that have come back or not responded to standard treatments. The therapy in…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 13:34 UTC